<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>中睿医药评论 | wechat-feeds</title><link>http://MjM5NDA5MTQ5MQ.favicon.privacyhide.com/favicon.ico</link><description>中睿咨询致力于帮助中国本土大中型企业和具备核心资源的中小成长型企业构建企业战略和战术落地高度融合的一体化的体系。推动企业在明确战略方向指引下，实现持续成长！</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 25 Mar 2021 19:39:10 +0800</pubDate><image><url>http://MjM5NDA5MTQ5MQ.favicon.privacyhide.com/favicon.ico</url><title>中睿医药评论 | wechat-feeds</title><link>http://MjM5NDA5MTQ5MQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>新版医保目录抗癌药价格盘点</title><link>https://mp.weixin.qq.com/s/3edDT-Yd5c3FGEawkVRWug</link><description></description><content:encoded><![CDATA[新版医保目录抗癌药价格盘点]]></content:encoded><pubDate>Thu, 25 Mar 2021 18:32:24 +0800</pubDate></item><item><title>基石药业「普拉替尼胶囊」正式附条件批准，还有 3 款重磅产品预计今年获批</title><link>https://mp.weixin.qq.com/s/22xLZvAY9fLxOIuNVjn4Yg</link><description></description><content:encoded><![CDATA[基石药业「普拉替尼胶囊」正式附条件批准，还有 3 款重磅产品预计今年获批]]></content:encoded><pubDate>Wed, 24 Mar 2021 17:28:21 +0800</pubDate></item><item><title>两款新药拟获突破性疗法认定，来自信达、亚盛</title><link>https://mp.weixin.qq.com/s/kOn9OjuEgmoGns-OjNHYOA</link><description></description><content:encoded><![CDATA[两款新药拟获突破性疗法认定，来自信达、亚盛]]></content:encoded><pubDate>Mon, 22 Mar 2021 20:09:19 +0800</pubDate></item><item><title>基石药业精准靶向疗法「阿泊替尼片」即将获批上市</title><link>https://mp.weixin.qq.com/s/k7j_OIZIJ9hPsMMh1Lv51w</link><description></description><content:encoded><![CDATA[基石药业精准靶向疗法「阿泊替尼片」即将获批上市]]></content:encoded><pubDate>Fri, 19 Mar 2021 17:21:54 +0800</pubDate></item><item><title>6款新药拟纳入突破性治疗品种！来自恒瑞医药、微芯生物、君实生物、誉衡药业、诺和诺德等</title><link>https://mp.weixin.qq.com/s/zD-C09CzYkEo9gXJ3vyCbQ</link><description></description><content:encoded><![CDATA[6款新药拟纳入突破性治疗品种！来自恒瑞医药、微芯生物、君实生物、誉衡药业、诺和诺德等]]></content:encoded><pubDate>Wed, 17 Mar 2021 17:58:06 +0800</pubDate></item><item><title>2个重磅国产创新药上市！</title><link>https://mp.weixin.qq.com/s/e5-MQ-7tg1NX8JaGs2VUvA</link><description></description><content:encoded><![CDATA[2个重磅国产创新药上市！]]></content:encoded><pubDate>Mon, 15 Mar 2021 17:20:04 +0800</pubDate></item><item><title>1.7亿元！石药集团获一款IL-4Rα单抗中国区独家权益</title><link>https://mp.weixin.qq.com/s/qPegTimYjYonnOroO2dASw</link><description></description><content:encoded><![CDATA[1.7亿元！石药集团获一款IL-4Rα单抗中国区独家权益]]></content:encoded><pubDate>Mon, 15 Mar 2021 17:20:04 +0800</pubDate></item><item><title>荣昌生物首个原创新药泰爱®正式获批，开启系统性红斑狼疮“双靶”时代</title><link>https://mp.weixin.qq.com/s/HGxXSlYWWfC0y9VPB1r4VA</link><description></description><content:encoded><![CDATA[荣昌生物首个原创新药泰爱®正式获批，开启系统性红斑狼疮“双靶”时代]]></content:encoded><pubDate>Fri, 12 Mar 2021 18:03:01 +0800</pubDate></item><item><title>CDE发布第四十一批化学仿制药参比制剂目录</title><link>https://mp.weixin.qq.com/s/5AfDqFxSTUxw0DBEs7upmg</link><description></description><content:encoded><![CDATA[CDE发布第四十一批化学仿制药参比制剂目录]]></content:encoded><pubDate>Fri, 12 Mar 2021 18:03:01 +0800</pubDate></item><item><title>三代EGFR竞争来袭！石药2亿元引进一款！国内独家授权</title><link>https://mp.weixin.qq.com/s/me8fcP7PLCA2hJOQclv5Sg</link><description></description><content:encoded><![CDATA[三代EGFR竞争来袭！石药2亿元引进一款！国内独家授权]]></content:encoded><pubDate>Wed, 10 Mar 2021 17:34:32 +0800</pubDate></item><item><title>符合第 5 批集采品种已达 86 个，胰岛素或启动专项采购！</title><link>https://mp.weixin.qq.com/s/nk89eeSni6sslU-zb2HVgg</link><description></description><content:encoded><![CDATA[符合第 5 批集采品种已达 86 个，胰岛素或启动专项采购！]]></content:encoded><pubDate>Wed, 10 Mar 2021 17:34:32 +0800</pubDate></item><item><title>首仿！正大天晴「仑伐替尼胶囊」即将获批上市</title><link>https://mp.weixin.qq.com/s/YdL8UdCk0qQDZmGH2Ovrtg</link><description></description><content:encoded><![CDATA[首仿！正大天晴「仑伐替尼胶囊」即将获批上市]]></content:encoded><pubDate>Mon, 08 Mar 2021 18:35:02 +0800</pubDate></item><item><title>符合第 5 批集采品种已达 86 个，胰岛素或启动专项采购！</title><link>https://mp.weixin.qq.com/s/KxP2ST8LEgeGa2TclCrzhA</link><description></description><content:encoded><![CDATA[符合第 5 批集采品种已达 86 个，胰岛素或启动专项采购！]]></content:encoded><pubDate>Mon, 08 Mar 2021 18:35:02 +0800</pubDate></item><item><title>迈瑞、迈克、新产业、华大、万孚、万泰等31家上市IVD企业业务线拆解大全</title><link>https://mp.weixin.qq.com/s/rkZgmzFJdSK4NXj9b3qakA</link><description></description><content:encoded><![CDATA[迈瑞、迈克、新产业、华大、万孚、万泰等31家上市IVD企业业务线拆解大全]]></content:encoded><pubDate>Fri, 05 Mar 2021 16:36:50 +0800</pubDate></item><item><title>贝达药业三代 EGFR 抑制剂报上市，四代在路上，肺癌靶向药组合发力！</title><link>https://mp.weixin.qq.com/s/rLQkCHKR-w1Ic2io-qG_mA</link><description></description><content:encoded><![CDATA[贝达药业三代 EGFR 抑制剂报上市，四代在路上，肺癌靶向药组合发力！]]></content:encoded><pubDate>Fri, 05 Mar 2021 16:36:50 +0800</pubDate></item></channel></rss>